ATHENEX Inc. and Eli Lilly and Co. are collaborating on a study to evaluate the safety and tolerability of oraxol, an oral form of paclitaxel, in combination with Cyramza (ramucirumab), a vascular endothelial growth factor Receptor 2 antagonist, in patients with advanced gastric (stomach) and esophageal cancer. Patient enrollment, expected to start next year, is...
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
